TY - JOUR
T1 - Outcome of living-donor lobar lung transplantation using a single donor
AU - Date, Hiroshi
AU - Shiraishi, Takeshi
AU - Sugimoto, Seiichiro
AU - Shoji, Tsuyoshi
AU - Chen, Fengshi
AU - Hiratsuka, Masafumi
AU - Aoyama, Akihiro
AU - Sato, Masaaki
AU - Yamane, Masaomi
AU - Iwasaki, Akinori
AU - Miyoshi, Shinichiro
AU - Bando, Toru
AU - Oto, Takahiro
PY - 2012/9
Y1 - 2012/9
N2 - Objective: Living-donor lobar lung transplantation usually requires 2 healthy donors who donate either a right or a left lower lobe; however, finding 2 healthy donors is difficult. Several case reports have been published on successful living-donor lobar lung transplantation using a single donor; however, little is known about its outcome. Methods: We retrospectively investigated 14 critically ill patients who had undergone single living-donor lobar lung transplantation at 3 lung transplant centers in Japan. There were 10 female and 4 male patients, including 10 children and 4 adults. Size matching was assessed by estimated graft forced vital capacity and 3-dimensional computed tomography volumetry. The diagnoses included complications of allogeneic hematopoietic stem cell transplantation (n = 6), pulmonary hypertension (n = 4), and others (n = 4). Results: At a mean follow-up of 45 months (range, 2-128), the 3- and 5-year survival rate was 70% and 56%, respectively. There were 4 early deaths, for a hospital mortality of 29%, with 1 additional death at 40 months. The main cause of early death was primary graft dysfunction, most likely related to size mismatching. The survival among these 14 patients was significantly worse than the survival in a group of 78 patients undergoing bilateral living-donor lobar lung transplantation during the same period (P = .044). Conclusions: Single living-donor lobar lung transplantation provides acceptable results for sick patients who would die soon otherwise. However, bilateral living-donor lobar lung transplantation appears to be a better option if 2 living donors are found.
AB - Objective: Living-donor lobar lung transplantation usually requires 2 healthy donors who donate either a right or a left lower lobe; however, finding 2 healthy donors is difficult. Several case reports have been published on successful living-donor lobar lung transplantation using a single donor; however, little is known about its outcome. Methods: We retrospectively investigated 14 critically ill patients who had undergone single living-donor lobar lung transplantation at 3 lung transplant centers in Japan. There were 10 female and 4 male patients, including 10 children and 4 adults. Size matching was assessed by estimated graft forced vital capacity and 3-dimensional computed tomography volumetry. The diagnoses included complications of allogeneic hematopoietic stem cell transplantation (n = 6), pulmonary hypertension (n = 4), and others (n = 4). Results: At a mean follow-up of 45 months (range, 2-128), the 3- and 5-year survival rate was 70% and 56%, respectively. There were 4 early deaths, for a hospital mortality of 29%, with 1 additional death at 40 months. The main cause of early death was primary graft dysfunction, most likely related to size mismatching. The survival among these 14 patients was significantly worse than the survival in a group of 78 patients undergoing bilateral living-donor lobar lung transplantation during the same period (P = .044). Conclusions: Single living-donor lobar lung transplantation provides acceptable results for sick patients who would die soon otherwise. However, bilateral living-donor lobar lung transplantation appears to be a better option if 2 living donors are found.
UR - http://www.scopus.com/inward/record.url?scp=84865679241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865679241&partnerID=8YFLogxK
U2 - 10.1016/j.jtcvs.2012.05.054
DO - 10.1016/j.jtcvs.2012.05.054
M3 - Article
C2 - 22717276
AN - SCOPUS:84865679241
SN - 0022-5223
VL - 144
SP - 710
EP - 715
JO - Journal of Thoracic and Cardiovascular Surgery
JF - Journal of Thoracic and Cardiovascular Surgery
IS - 3
ER -